Article Sidebar

Published
June 7, 2026
Download
PDF
Statistic
Read Counter : 0

Main Article Content

Abstract

Background. Epstein-Barr virus is a herpes virus member infects many people across the world. In people of strong immune status, the infection mainly became asymptomatic and is well controlled, while in immunocompromised as hemodialysis patients, the EBV can cause severe illness due to loss of kidney function.


Objective. This study objective was to detection of presence the IgG and IgM antibodies against EBV in HD patients and the suspected connection between produced antibodies and hematological parameters (CBC).


Methods. During the period started from November 2025 to the end of January 2026, Blood samples obtained from 270 chronic kidney disease’s patients were collected. As 137 samples were taken from hemodialytic men, and 133 samples are obtained from women patients. The age group of patients who were chosen in the study varied from 20 to 70. Serum samples were examined for EBV-IgG/IgM antibodies. Whole blood using for analysis complete blood count (CBC) by automated hematology analyzers.


 Results.Levels of specific viral IgG/IgM antibodies related to EBV genome was 54.8% and 10.4% respectively. The level IgM antibodies was statistically significant and were measured higher in the age group 20-30 years to 24% than what was detected in other age groups, and lowest among those aged 51–60 years (3.4%). The availability of IgM antibodies specific for EBV indicated to their correlation with the younger age group, duration of dialysis and frequent dialysis per week.


Conclusion. No statistical stratified difference between patients with EBV-IgG and age and frequency dialysis.

Keywords

Epstein Barr virus (EBV) EBNA1 EBNA2 hemodialytic patients chronic kidney disease (CKD)

Article Details

License

Copyright (c) 2026 Tamarh Jasim Mohamed, Mohammed Jasim Mohammed Shallal, Haider Mohammed Alyasiri

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

  1. Basem Z, Jameel H. Detection of Epstein-Barr virus among chronic kidney disease patients in Najaf, Iraq. Curr Issues Pharm Med Sci. 2024;37(1):47-51. https://doi.org/10.2478/cipms-2024-0008.
  2. Yasir SJ, Marzoq HS. Detection of Epstein-Barr virus in hemodialysis cases in Al-Najaf governorate. In: AIP Conference Proceedings. 2022;2386(1):020020. Available from: https://doi.org/10.1063/5.0067740.
  3. López-Valencia D, Medina-Ortega Á, Hoyos-Samboní DF, Saavedra-Torres JS, Salguero C. Epstein-Barr virus infection as a predisposing factor for multiple sclerosis: an update from molecular biology, immunology and epidemiology. Rev Fac Med (Bogota). 2019;67(3):493-501. https://doi.org/10.15446/revfacmed.v67n3.73319.
  4. Kempkes B, Ling PD. EBNA2 and its coactivator EBNA-LP. Curr Top Microbiol Immunol.2015;391:35-59. https://doi.org/10.1007/978-3-319-22834-1_2.
  5. Goh ZS, Griva K. Anxiety and depression in patients with end-stage renal disease: impact and management challenges—a narrative review. Int. J. Nephrol. Renovasc. Dis. 2018;11:93-102..https://doi.org/10.2147/IJNRD.S126615.
  6. Moehl BS, Chen J and Longnecker R (2019). Gamma-herpesvirus entry and fusion: A tale how two human pathogenic viruses enter their host cells. In Advances in virus research. 2019; 104:313-343. https://doi.org/10.1016/bs.aivir.2019.02.003.
  7. Thorley-Lawson DA (2015). EBV persistence—introducing the virus. Epstein Barr Virus Volume 1: One Herpes Virus: Many Diseases, 151-209. https://doi.org/10.1007/978-3-319-22822-8_8.
  8. Murata T, Sugimoto A, Inagaki T, Yanagi Y, Watanabe T, Sato Y & Kimura H; Molecular basis of epstein–barr virus latency establishment and lytic reactivation. Viruses. 2021; 13 (12):2344. https://doi.org/10.3390/v13122344.
  9. Ihsan EA, Mohammed LM, & Ali WM; (2023). Prevalence of Epstein-Barr virus among hemodialysis patients in Kirkuk city. NTU Journal of Pure Sciences. 2023; 2(4):17-22. https://doi.org/10.56286/ntujps.v2i4.433.
  10. Ibrahim MN, Alhadi MS, Elbadawy WY; Serodetection of Cytomegalovirus and Epstein-Barr virus antibodies among hemodialysis patients. Biomed Pharmacol J. 2022: 15(1). https://doi.org/10.13005/bpj/2378.
  11. Al-Azzawy MA, Tawfiq SK, Qader SM; Detection of EBV and CMV Coinfection Among Patients Under Hemodialysis. International Journal of Health Sciences, (II). 2023; 4456-4463. https://doi.org/10.53730/ijhs.v17nS1.11482.
  12. Samiei RN, Mahmoudv and S, Shokri S, Makvandi M, Shahbazian H, Pirmoradi R, & Nowrozi S; The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran. Iranian Journal of Microbiology. 2019; 11(1): 75. https://doi.org/10.18502/ijm.v11i1.709.
  13. Deeba E, Koptides D, Gaglia E, Constantinou A, Lambrianides A, Pantzaris M, Christodoulou C; Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients. Molecular immunology. 2019; 105:270-275. https://doi.org/10.1016/j.molimm.2018.11.019.
  14. Hameed MS, & Kadhim MJ; Molecular and Serological Detection of Epstein-Barr virus (EBV) among Hemodialysis Patients in Karbala Province/ Iraq. Journal of University of Babylon for Pure and Applied Sciences. 2018; 26(1). https://doi.org/10.29196/jubpas.v26i1.1436.
  15. Rostgaard K, Balfour Jr H H, Jarrett R, Erikstrup C, Pedersen O, Ullum H & Hjalgrim H; Primary Epstein-Barr virus infection with and without infectious mononucleosis. PloS one, 2019; 14(12): e0226436. https://doi.org/10.1371/journal.pone.0226436.
  16. Eiz-Vesper B, Ravens S, Maecker-Kolhoff B. αβ and γδ T-cell responses to Epstein-Barr virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients. Curr Opin Immunol. 2023;82:102305. https://doi.org/10.1016/j.coi.2023.102305.
  17. Jalil MB, Al Atbee MYN. Seroprevalence of Epstein–Barr virus among hemodialysis patients: post-exposure analysis. Kidneys. 2023;14(4):559. https://doi.org/10.65327/kidneys.v14i4.559.
  18. Samiei RN, Mahmoudvand S, Shokri S, Makvandi M, Shahbazian H, Pirmoradi R, Nowrozi S. The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran. Iran J Microbiol. 2019;11(1):75-79. https://doi.org/10.18502/ijm.v11i1.709.
  19. Xiong G, Zhang B, Huang MY, Zhou H, Chen LZ, Feng QS, Zeng YX; Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One. 2014; 9(6): e99857. https://doi.org/10.1371/journal.pone.0099857.
  20. Ali HM, Al-Shuwaikh AM, Manuti JK. Detection of Torque Teno virus antigen and associated risk factors among hemodialysis patients. Wiad Lek. 2022;75(3):624-628. https://doi.org/10.36740/WLek202203110.
  21. Asaduzzaman M, Shobnam A, Farukuzzaman MD, Gaffar A, Juliana FM, Sharker T, Dutta KK, Islam MJ. Assessment of red blood cell indices, white blood cells, platelet indices and procalcitonin of chronic kidney disease patients under hemodialysis. Int J Health Sci Res. 2018;8:98-109. https://doi.org/10.4103/ijhsr.ijhsr_2018.
  22. Raad Y. Hematological parameter of the blood count in patients undergoing hemodialysis. Technium BioChemMed. 2021;2(1):32-40. https://doi.org/10.47577/biochemmed.v2i1.2611.
  23. Kahdina M, Mardiana N and Fauziah D; Levels of hemoglobin, leukocytes, and platelets of chronic kidneydisease patients undergoing hemodialysis in Surabaya. Biomolecular and Health Science Journal. 2018, 1(1): 29-33. DOI: org/10.20473/bhsj. v1i1.8190. https://doi.org/10.20473/bhsj.v1i1.8190.
  24. Zeng W, Liu G, Luan Q, Yang C, Luo X, Zhu Z, Yu X; Epstein-Barr Virus Promotes Inflammatory Cytokine Production in Human Gingival Fibroblasts. Int Dent J. 2024;74(3):607-615. https://doi.org/10.1016/j.identj.2023.12.006.
  25. Lin J, Chen X, Wu H, Chen X, Hu X, Xu J; Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection. Am J Transl Res. 2021;13(11):12797-12806. PMID: 34956494; PMCID: PMC8661241. DOI link: https://doi.org/10.62347/.

Similar Articles

You may also start an advanced similarity search for this article.